Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eye Development

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    160 result(s) found for: Eye Development. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2016-002172-27 Sponsor Protocol Number: NGF0116 Start Date*: 2016-11-09
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A 8 weeks, Phase II, single-centre, randomized, double-masked, vehicle-controlled, parallel group study with 4 weeks of follow-up to evaluate preliminary efficacy and safety of recombinant human Ne...
    Medical condition: patients after cataract and refractive surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002823-46 Sponsor Protocol Number: LT4030-201 Start Date*: 2018-09-11
    Sponsor Name:Laboratoires THÉA; Research and Development Department
    Full Title: Efficacy and safety assessment of T4030 eye drops (unpreserved fixed combination of bimatoprost 0.01% and timolol 0.1% or 0.5%) versus Ganfort® UD (Unit Dose) in ocular hypertensive or glaucomatous...
    Medical condition: Glaucoma, ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003515-10 Sponsor Protocol Number: BP41783 Start Date*: 2021-03-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A LONGITUDINAL, BIOMARKER STUDY OF ANTI-VEGF, TO EXPLORE THE RELATIONSHIP BETWEEN AQUEOUS HUMOR COMPOSITION AND MULTIMODAL RETINAL IMAGING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABET...
    Medical condition: Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD) and Treatment Naïve diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001598-93 Sponsor Protocol Number: C-02-60 Start Date*: 2005-07-05
    Sponsor Name:Alcon Research Limited
    Full Title: An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) versus Sham Administration in Patients (Enrolled in Study ...
    Medical condition: non-exudative age related macular degeneration (dry AMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003298-90 Sponsor Protocol Number: OPT-302-1003 Start Date*: 2018-12-07
    Sponsor Name:Opthea Ltd
    Full Title: Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema
    Medical condition: Persistent central-involved diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2017-002698-20 Sponsor Protocol Number: OPT-302-1002 Start Date*: 2018-02-07
    Sponsor Name:Opthea Ltd
    Full Title: A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)
    Medical condition: Neovascular age-related macular degeneration (wet AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005556-25 Sponsor Protocol Number: OFT-ETAMSILATO-4.2.2 Start Date*: 2015-05-11
    Sponsor Name:Investigacion Independiente
    Full Title: Open extension study for patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulatedcontrolled treatment to evaluate safety and efficacy o...
    Medical condition: Aged related macula degeneration (ARMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002931-32 Sponsor Protocol Number: APL2-GA-305 Start Date*: 2021-09-17
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3 open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) CZ (Ongoing) PL (Ongoing) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003664-41 Sponsor Protocol Number: PMS/LEVO-001-06-2012 Start Date*: 2013-07-04
    Sponsor Name:Balkanpharma-Razgrad AD
    Full Title: Open-labeled, randomized, comparative clinical study of efficacy and safety of Levofloxan 0,5% eye drops in patients with Acute Bacterial Conjunctivitis.
    Medical condition: Acute Bacterial Conjunctivitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-003979-18 Sponsor Protocol Number: LT4030-301 Start Date*: 2021-04-15
    Sponsor Name:Laboratoires THEA
    Full Title: Efficacy and Safety Assessment of T4030 Eye Drops versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.
    Medical condition: Primary open-angle glaucoma or Ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) HU (Completed) BG (Completed) BE (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-001810-14 Sponsor Protocol Number: PSV-FAI-001 Start Date*: 2013-10-30
    Sponsor Name:pSivida Corporation
    Full Title: A PHASE III, MULTI-NATIONAL, MULTI-CENTER, RANDOMIZED, MASKED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A FLUOCINOLONE ACETONIDE INTRAVITREAL (FAI) INSERT IN SUBJECTS WITH CHRONIC NON-INFECTIOUS...
    Medical condition: chronic non-infectious uveitis affecting the posterior segment of the eye
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000113-31 Sponsor Protocol Number: TED01RV Start Date*: 2014-07-14
    Sponsor Name:River Vision Development Corporation
    Full Title: A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks...
    Medical condition: Thyroid-Associated Ophthalmopathy / Graves' Ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002944-28 Sponsor Protocol Number: DM2115403 Start Date*: 2012-02-17
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficac...
    Medical condition: Diabetic macular edema with centre involvement
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003407-34 Sponsor Protocol Number: pre-CIN Start Date*: 2021-06-01
    Sponsor Name:Oslo University Hospital
    Full Title: A randomized clinical three-arm trial comparing inflammation and cystoid macular edema for the medication regimens preoperative and postoperative topical NSAIDs to only postoperative topical NSAIDs...
    Medical condition: Cataract surgery, and the medical treatment is anti-inflammatory eye drops to treat (and prevent) intraocular inflammation and development og cystoid macular edema.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005222-29 Sponsor Protocol Number: LT2347-PIII-12/13 Start Date*: 2014-12-19
    Sponsor Name:Laboratoires THÉA
    Full Title: Efficacy and Safety assessment of fixed combination unpreserved Latanoprost eye drops and Timolol 0.5% (T2347) versus Xalacom® in ocular hypertensive or glaucomatous patients. Phase III, internati...
    Medical condition: glaucoma, ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) ES (Completed) EE (Completed) HU (Ongoing) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001436-22 Sponsor Protocol Number: APL2-303 Start Date*: 2018-12-07
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic A...
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004325-16 Sponsor Protocol Number: RC31/16/8407 Start Date*: 2016-12-22
    Sponsor Name:University Hospital of Toulouse
    Full Title: Long term evaluation of infants aged from 3 to 4 years old included in the OTBB2 study (repeated administrations of oxytocin in infants with PWS aged from 0 to 6 months) and comparison with not tre...
    Medical condition: Prader Willi Syndrom
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005686-11 Sponsor Protocol Number: SP878 Start Date*: 2006-02-21
    Sponsor Name:SCHWARZ PHARMA Deutschland GmbH
    Full Title: CONFIRMATORY, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROSTAGLANDIN E1 IN SUBJECTS WITH DRY AGE-RELATED MACULAR DEGENER...
    Medical condition: Patients with dry age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023216-14 Sponsor Protocol Number: HP-AM2-001 Start Date*: 2011-03-15
    Sponsor Name:Hermo Pharma Ltd
    Full Title: A Phase II, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of 10 Weeks Treatment with Fluoxetine 20 mg and Computer Software-Based Training in Adult Patients with Amblyopia
    Medical condition: treatment of adult amblyopia - amblyopia due to myopic or hyperopic anisometropia, or, congenital esotropia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10065008 Amblyopia unilateral LLT
    14.1 10015919 - Eye disorders 10015475 Esotropia LLT
    14.1 10015919 - Eye disorders 10042158 Strabismic amblyopia LLT
    14.1 10015919 - Eye disorders 10001906 Amblyopia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004042-96 Sponsor Protocol Number: 32-009 Start Date*: 2015-05-05
    Sponsor Name:Santen Incorporated
    Full Title: A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects with Non-Infectious Uveitis of the Posterior...
    Medical condition: non -infectious Uveitis of the Posterior Segment of the Eye
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA